Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 26

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 26
---
 and proceeds to us are not presently determinable and may be substantially less than the maximum amounts contemplated in this prospectus. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. 9 Our management has broad discretion as to the use of the net proceeds from this offering. Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled “Use of Proceeds.” Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our Common Stock price to decline. If you purchase securities in this offering, you will experience immediate and substantial dilution and may experience additional dilution in the future. Investors purchasing shares of our Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Offered Common Warrants in this offering will pay a price per share that substantially exceeds the as adjusted net tangible book value per share. As a result, investors purchasing our Common Stock and accompanying Offered Common Warrants in this offering will incur immediate dilution of $1.05 per share, representing the difference between the assumed public offering price of $2.34 per share, which is the last reported sale price of our Common Stock on the Nasdaq Global Market on January 17, 2025, and our pro forma net tangible book value as of September 30, 2024, which information as of September 30, 2024 gives retroactive effect to the 1 for 100 ratio of our Reverse Stock Split. For more information on the dilution you may suffer as a result of investing in this offering, see “Dilution.” Because there is no minimum required for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. We have not